Menu
Close
We revolutionise the discovery and development of bispecific antibody drug conjugates (bsADCs) to find the right treatment for any type of cancer.
Our Solution
Bispecific ADCs (bsADCs) have the potential to revolutionise ADCs as dual targeting enables improved function and cell selectivity. Our technology allows us to quickly design and test new bsADCs with complex structures and diverse target and payload combinations.
The discovery of bsADCs is held back by an inability to rapidly generate and screen new therapeutic candidates. Valink can build thousands of drug candidates in days
from a variety of components, including antibody fragments and small molecules.
Using our LiliumX™ discovery platform, we solve the fundamental challenges of bsADC discovery. This allows us to unlock unprecedented therapies in solid tumours
and beyond.
We target solid tumours with bispecific antibody-drug conjugates. By aiming at two markers at once, we can improve payload delivery and more accurately differentiate between malignant and healthy tissues.
Contact Us
United States
Valink Therapeutics Inc
50 Milk Street,
16th floor,
Boston,
MA 02109
United Kingdom
Valink Therapeutics Ltd
Imperial I-Hub,
84 Wood Lane,
London,
W12 0BZ
Message sent successfully.
Oops, something happened. Please try again.
United Kingdom
Valink Therapeutics Ltd
Imperial I-Hub,
84 Wood Lane,
London,
W12 0BZ
United States
Valink Therapeutics Inc
50 Milk St.,
16th floor,
Boston,
MA 02109
.png)
